Author

Dan Vorhaus

  • FDA

    House Holds mHealth Hearings, FDA Promises Final Guidance Forthcoming

    By Dan Vorhaus [Cross-posted from Genomics Law Report] Three days of hearings by a House of Representatives committee concluded yesterday with a pledge from an FDA official to finalize long-awaited guidance on the regulation of…

    House Holds mHealth Hearings, FDA Promises Final Guidance Forthcoming

  • FDA

    mHealth on the Horizon: Federal Agencies Paint Regulatory Landscape with Broad Brushstrokes

    By Dan Vorhaus and Phil Ross (cross-posted from Genomics Law Report) For years, and with increasing frequency, health care and information technology companies have touted the potential of mobile medical and health applications and technologies to…

    mHealth on the Horizon: Federal Agencies Paint Regulatory Landscape with Broad Brushstrokes

  • Biotechnology

    Myriad Updates: Clinical Data as Trade Secrets and a Pending Certiorari Decision

    By Dan Vorhaus (Cross-Posted from Genomics Law Report) Earlier this month, my colleagues John Conley, Robert Cook-Deegan, James Evans and I published a policy article in the European Journal of Human Genetics (EJHG) entitled “The next controversy…

    Myriad Updates: Clinical Data as Trade Secrets and a Pending Certiorari Decision

  • Biotechnology

    DNA DTC: The Return of Direct to Consumer Whole Genome Sequencing

    By Dan Vorhaus (Cross-Posted from Genomics Law Report) This morning, Gene By Gene, Ltd. – better known as the parent company of the popular genetic genealogy provider Family Tree DNA – formally announced a corporate reorganization that includes the debut of a new…

    DNA DTC: The Return of Direct to Consumer Whole Genome Sequencing